Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03895112
What this trial is testing

MPN-RC 118 AVID200 in Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis+2 more
John Mascarenhas 21
Large-scale testing (Phase 3)Study completedNCT02101268
What this trial is testing

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Sierra Oncology LLC - a GSK company 156
Early research (Phase 1)Ended earlyNCT03373877
What this trial is testing

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more
Samus Therapeutics, Inc. 4
Testing effectiveness (Phase 2)Study completedNCT01392443
What this trial is testing

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Who this might be right for
Primary Myelofibrosis (MF)Post-Polycythemia Vera (PV) MFPost-Essential Thrombocythemia (ET) MF
Novartis Pharmaceuticals 120
Testing effectiveness (Phase 2)Ended earlyNCT02730884
What this trial is testing

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Who this might be right for
LeukemiaMyelofibrosisAnemia+1 more
M.D. Anderson Cancer Center 3
Not applicableStudy completedNCT05044026
What this trial is testing

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals 1,012
Testing effectiveness (Phase 2)Study completedNCT01981850
What this trial is testing

RO7490677 In Participants With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPolycythemia VeraPost-Essential Thrombocythemia Myelofibrosis
Hoffmann-La Roche 125
Testing effectiveness (Phase 2)Active Not RecruitingNCT04446650
What this trial is testing

Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Who this might be right for
Primary Myelofibrosis
Bristol-Myers Squibb 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT05467800
What this trial is testing

Study of Canakinumab in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisET-MF+2 more
John Mascarenhas 14
Not applicableLooking for participantsNCT07362225
What this trial is testing

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Who this might be right for
Polycythemia VeraET (Essential Thrombocythemia)Polycythemia Vera (PV)+52 more
MPN Research Foundation 5,000
Testing effectiveness (Phase 2)Study completedNCT01732445
What this trial is testing

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

Who this might be right for
AnemiaPrimary MyelofibrosisSecondary Myelofibrosis
Mayo Clinic 14
Testing effectiveness (Phase 2)Study completedNCT01423851
What this trial is testing

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
NS Pharma, Inc. 77
Testing effectiveness (Phase 2)Looking for participantsNCT06327100
What this trial is testing

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-Essential Thrombocytosis Myelofibrosis
M.D. Anderson Cancer Center 33
Early research (Phase 1)Active Not RecruitingNCT07340138
What this trial is testing

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Novartis Pharmaceuticals 3
Testing effectiveness (Phase 2)WithdrawnNCT04054245
What this trial is testing

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Who this might be right for
Myelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary Myelofibrosis
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Study completedNCT02087059
What this trial is testing

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Who this might be right for
Primary Myelofibrosis (MF)
Novartis Pharmaceuticals 51
Large-scale testing (Phase 3)Looking for participantsNCT06479135
What this trial is testing

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
MyelofibrosisPost-PV MFPost-ET Myelofibrosis+2 more
Kartos Therapeutics, Inc. 600
Early research (Phase 1)Ended earlyNCT03935555
What this trial is testing

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Samus Therapeutics, Inc. 11
Testing effectiveness (Phase 2)Study completedNCT04629508
What this trial is testing

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Who this might be right for
MyelofibrosisPolycythemia VeraThrombocythemia
Incyte Corporation 4
Testing effectiveness (Phase 2)Study completedNCT04217993
What this trial is testing

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis(Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 51
Next Page